Ftse Mib
34.135,06
-0,70%
DAX
18.491,71
-0,58%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
62.745,13
-3,25%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Processa Pharmaceuticals Inc (PCSA) Processa Pharmaceuticals Inc (PCSA) Notizie

PCSA

Processa Pharmaceuticals (PCSA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA
DataOraFonteTitoloSimboloCompagnia
05/04/202214:30GlobeNewswire Inc.Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of GastroparesisNASDAQ:PCSAProcessa Pharmaceuticals Inc
04/04/202223:58Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202222:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
30/03/202222:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
24/03/202221:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PCSAProcessa Pharmaceuticals Inc
24/03/202221:16Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PCSAProcessa Pharmaceuticals Inc
23/03/202213:30GlobeNewswire Inc.Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
10/03/202214:30GlobeNewswire Inc.Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
26/01/202214:15GlobeNewswire Inc.Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022NASDAQ:PCSAProcessa Pharmaceuticals Inc
06/01/202223:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/11/202112:15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PCSAProcessa Pharmaceuticals Inc
11/11/202122:05GlobeNewswire Inc.Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
04/11/202113:15GlobeNewswire Inc.Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim AnalysisNASDAQ:PCSAProcessa Pharmaceuticals Inc
26/10/202114:30GlobeNewswire Inc.Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
12/10/202114:30GlobeNewswire Inc.Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of GastroparesisNASDAQ:PCSAProcessa Pharmaceuticals Inc
20/09/202120:56Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
20/09/202120:56Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
16/09/202117:05GlobeNewswire Inc.Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
16/09/202114:30GlobeNewswire Inc.Processa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:PCSAProcessa Pharmaceuticals Inc
23/08/202122:00GlobeNewswire Inc.Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27NASDAQ:PCSAProcessa Pharmaceuticals Inc
12/08/202123:15GlobeNewswire Inc.Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate UpdateNASDAQ:PCSAProcessa Pharmaceuticals Inc
10/08/202123:03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PCSAProcessa Pharmaceuticals Inc
06/08/202114:30GlobeNewswire Inc.Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. ESTNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/08/202115:51TipRanksBuy These 3 Stocks Before They Double (or More), Say AnalystsNASDAQ:PCSAProcessa Pharmaceuticals Inc
04/08/202114:30GlobeNewswire Inc.Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal CancerNASDAQ:PCSAProcessa Pharmaceuticals Inc
27/07/202114:30GlobeNewswire Inc.Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ETNASDAQ:PCSAProcessa Pharmaceuticals Inc
12/07/202112:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PCSAProcessa Pharmaceuticals Inc
06/07/202114:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ETNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/06/202122:03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:PCSAProcessa Pharmaceuticals Inc
17/06/202115:15GlobeNewswire Inc.PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117NASDAQ:PCSAProcessa Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA

La tua Cronologia

NASDAQ
CTEL
AQEU
GM
Generali
BIT
P23H75
NLBNPIT23H75 20241218 6200
NYSE
STZ.B
Constellation Brands
LSE
BN11
Citi Fun 26
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network